Daily Stock Setups

Medicis receives additional Notice of Allowance for SOLODYN 90mg

Posted on: Mon, 20 Apr 2009 04:43:00 EDT

Symbols: MRX

Are you looking to increase your ETF knowledge?

Apr 20, 2009 (M2 EQUITYBITES via COMTEX) --
MRX | Quote | Chart | News | PowerRating -- Medicis (NYSE:MRX), a speciality pharmaceutical company, declared on 17
April the grant of an additional Notice of Allowance from the United
States Patent and Trademark Office (USPTO) for a US patent application
related to SOLODYN in 90mg tablet form.

The 90mg strength represented over 60% of total SOLODYN prescriptions
in the week ending 3 April 2009.

The patent application is US Application No. 11/695,539, entitled
"Minocycline Oral Dosage Forms For The Treatment Of Acne", and the
newly allowed claims include subject matter covering a
controlled-release oral dosage form of minocycline to treat acne.

These allowed patent claims, when issued, will enhance the intellectual
property protection of the SOLODYN brand, Medicis believes.

SOLODYN has one issued patent, US patent No. 5,908,838, which expires
in 2018, related to the use of the SOLODYN unique dissolution rate. The
product received a Notice of Allowance on a second application in early
April.

SOLODYN is the only branded oral minocycline approved for once daily
dosage in the treatment of inflammatory lesions of non-nodular moderate
to severe acne vulgaris in patients 12 years of age and older. The
product is available by prescription in 45mg, 90mg and 135mg extended
release tablet dosages.

Comments on this story may be sent to admin@m2.com

For full details on Medicis Pharmaceutical A (MRX) MRX. Medicis Pharmaceutical A (MRX) has Short Term PowerRatings at TradingMarkets. Details on Medicis Pharmaceutical A (MRX) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.